CL2022002830A1 - Anticuerpo anti-ox40 y usos del mismo - Google Patents

Anticuerpo anti-ox40 y usos del mismo

Info

Publication number
CL2022002830A1
CL2022002830A1 CL2022002830A CL2022002830A CL2022002830A1 CL 2022002830 A1 CL2022002830 A1 CL 2022002830A1 CL 2022002830 A CL2022002830 A CL 2022002830A CL 2022002830 A CL2022002830 A CL 2022002830A CL 2022002830 A1 CL2022002830 A1 CL 2022002830A1
Authority
CL
Chile
Prior art keywords
antibody
antigen
treating
preparation
conditions
Prior art date
Application number
CL2022002830A
Other languages
English (en)
Inventor
Yang Yizhen
Cai Yu
Li Xiong
Zhou Lei
Qing Weiguo
Su Wei-Guo
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CL2022002830A1 publication Critical patent/CL2022002830A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención provee un anticuerpo anti-OX40 o un fragmento que se une al antígeno del mismo, un método de preparación para el mismo y el uso para tratar enfermedades o condiciones relacionadas con OX40.
CL2022002830A 2020-04-17 2022-10-13 Anticuerpo anti-ox40 y usos del mismo CL2022002830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010304381 2020-04-17

Publications (1)

Publication Number Publication Date
CL2022002830A1 true CL2022002830A1 (es) 2023-06-09

Family

ID=78084656

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002830A CL2022002830A1 (es) 2020-04-17 2022-10-13 Anticuerpo anti-ox40 y usos del mismo
CL2022002829A CL2022002829A1 (es) 2020-04-17 2022-10-13 Anticuerpo anti-ox40 y usos del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2022002829A CL2022002829A1 (es) 2020-04-17 2022-10-13 Anticuerpo anti-ox40 y usos del mismo

Country Status (15)

Country Link
US (2) US20230242657A1 (es)
EP (2) EP4136116A1 (es)
JP (2) JP2023523395A (es)
KR (2) KR20230015328A (es)
CN (2) CN115461366A (es)
AR (2) AR121857A1 (es)
AU (2) AU2021256799A1 (es)
BR (2) BR112022020742A2 (es)
CA (2) CA3175407A1 (es)
CL (2) CL2022002830A1 (es)
IL (2) IL297292A (es)
MX (2) MX2022012915A (es)
PE (2) PE20230255A1 (es)
TW (2) TW202144424A (es)
WO (2) WO2021209019A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2925350T (pt) * 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
LT3126394T (lt) * 2014-03-31 2020-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš ox40 ir jų naudojimo būdai
JP2019530434A (ja) * 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
JP2021501801A (ja) * 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の処置に用いるための免疫刺激アゴニスト抗体
JP7479281B2 (ja) * 2017-11-24 2024-05-08 ユーキュア・（ベイジン）・バイオファーマ・カンパニー・リミテッド 抗ｏｘ４０抗体及びその用途
CN110092832B (zh) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 抗ox40抗体及其用途
WO2019178852A1 (zh) * 2018-03-23 2019-09-26 苏州丁孚靶点生物技术有限公司 Ox40抗原多肽及其用途
MX2020012567A (es) * 2018-05-23 2021-01-29 Beigene Ltd Anticuerpos anti-ox40 y metodos de uso.

Also Published As

Publication number Publication date
AU2021256799A1 (en) 2022-11-17
CN115461366A (zh) 2022-12-09
JP2023521475A (ja) 2023-05-24
AU2021256226A1 (en) 2022-11-17
PE20230682A1 (es) 2023-04-21
CA3175407A1 (en) 2021-10-21
IL297294A (en) 2022-12-01
EP4136117A1 (en) 2023-02-22
BR112022020742A2 (pt) 2022-12-20
TW202144424A (zh) 2021-12-01
KR20230015328A (ko) 2023-01-31
AR121857A1 (es) 2022-07-20
CA3175413A1 (en) 2021-10-21
MX2022012913A (es) 2022-11-14
PE20230255A1 (es) 2023-02-07
US20230242657A1 (en) 2023-08-03
BR112022020741A2 (pt) 2022-12-20
WO2021209019A1 (en) 2021-10-21
MX2022012915A (es) 2022-11-16
JP2023523395A (ja) 2023-06-05
CL2022002829A1 (es) 2023-06-09
CN115461367A (zh) 2022-12-09
WO2021209020A1 (en) 2021-10-21
TW202144423A (zh) 2021-12-01
US20230151105A1 (en) 2023-05-18
EP4136116A1 (en) 2023-02-22
AR121858A1 (es) 2022-07-20
IL297292A (en) 2022-12-01
KR20230015327A (ko) 2023-01-31
EP4136117A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
UY36692A (es) Anticuerpos anti-cd40 y usos de los mismos
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CL2020002103A1 (es) Anticuerpos anti-htra1 y metodos de uso de los mismos. (divisional solicitud 201801139)
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
BR112022021641A2 (pt) Tratamento de combinação de anticorpos anti-cd40 para câncer
BR112021016596A2 (pt) Anticorpo anti-pd-l1 e uso do mesmo
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2023000741A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos.
CL2021000483A1 (es) Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
CO2021000386A2 (es) Anticuerpos humanizados contra psma
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CL2022002727A1 (es) Anticuerpo anti-cd47 y usos del mismo
CL2022002829A1 (es) Anticuerpo anti-ox40 y usos del mismo
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
BR112019024230A2 (pt) combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
CL2021001021A1 (es) Anticuerpo anti-cldn18.2 y sus usos.
AR118736A1 (es) Anticuerpo anti-cldn18.2 y sus usos
AR122660A2 (es) Anticuerpos anti-pmel17 y conjugados de los mismos